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Vasopressin V1a receptors mediate the hypertensive
effects of [Pyr1]apelin-13 in the rat rostral ventrolateral
medulla
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1School of Clinical Sciences, University of Bristol, Bristol, UK
2School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences, University of Bristol, Bristol, UK
Key points
 Dysfunctions in CNS regulation of arterial blood pressure lead to an increase in sympathetic
nerve activity that participates in the pathogenesis of hypertension.
 The apelin-apelin receptor system affects arterial blood pressure homeostasis; however, the
central mechanisms underlying apelin-mediated changes in sympathetic nerve activity and
blood pressure have not been clarified.
 We explored the mechanisms involved in the regulation of [Pyr1]apelin-13-mediated cardio-
vascular control within the rostral ventrolateral medulla (RVLM) using selective receptor
antagonists.
 We show that [Pyr1]apelin-13 acts as a modulating neurotransmitter in the normotensive
RVLM to affect vascular tone through interaction with the vasopressin V1a receptor but that
[Pyr1]apelin-13-induced sympathoexcitation is independent of angiotensin II receptor type 1,
oxytocin, ionotropic glutamate and GABAA receptors.
 Our data confirm a role for the apelin peptide system in cardiovascular regulation at the level
of the RVLM and highlight that this system is a possible potential therapeutic target for the
treatment of hypertension.
Abstract Apelin is a ubiquitous peptide that can elevate arterial blood pressure (ABP)
yet understanding of the mechanisms involved remain incomplete. Bilateral microinjection
of [Pyr1]apelin-13 into the rostral ventrolateral medulla (RVLM), a major source of
sympathoexcitatory neurones, increases ABP and sympathetic nerve activity. We aimed to
investigate the potential involvement of neurotransmitter systems through which the apelin pre-
ssor response may occur within the RVLM. Adult male Wistar rats were anaesthetized and ABP
was monitored via a femoral arterial catheter. Bilateral RVLM microinjection of [Pyr1]apelin-13
significantly increased ABP (9 ± 1 mmHg) compared to saline (−1 ± 2mmHg; P < 0.001),
which was blocked by pretreatment with the apelin receptor antagonist, F13A (0 ± 1 mmHg;
P< 0.01). The rise in ABP was associated with an increase in the low frequency spectra of systolic
BP (13.9 ± 4.3% total power; P < 0.001), indicative of sympathetic vasomotor activation. The
[Pyr1]apelin-13-mediated pressor response and the increased low frequency spectra of systolic BP
responsewere fullymaintaineddespiteRVLMpretreatmentwith the angiotensin II type 1 receptor
antagonist losartan, the oxytocin receptor antagonist desGly-NH2, d(CH2)5[D-Tyr2,Thr4]OVT,
the ionotropic glutamate receptor antagonist kynurenate or the GABAA antagonist bicuculline
(P> 0.05). By contrast, the [Pyr1]apelin-13 induced pressor and sympathoexcitatory effects were
abolished by pretreatment of the RVLM with the vasopressin V1a receptor antagonist, SR 49059
(−1 ± 1 mmHg; 1.1 ± 1.1% total power, respectively; P < 0.001). These findings suggest that
the pressor action of [Pyr1]apelin-13 in the RVLM of normotensive rats is not mediated via
angiotensin II type 1 receptor, oxytocin, ionotropic glutamate or GABAA receptors but instead
involves a close relationship with the neuropeptide modulator vasopressin.
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Introduction
Dysfunctions in CNS regulation of blood pressure (BP)
lead to an increase in sympathetic nerve activity (SNA)
that participates in the pathogenesis of hypertension (Esler
et al. 2001). Chronic sympathetic hyperactivity is pre-
sent in a significant percentage of patients with essential
hypertension, and is responsible for more than 90% of
all hypertensive disorders (Carretero &Oparil, 2000). The
causative mechanisms of elevated SNA remain unclear,
although they probably involve both neural and humoral
mechanisms. Studies have implicated the apelin-apelin
receptor (APJ) system in the increase of SNA and in the
development of hypertension (Wu et al. 2014), although
the underlying mechanism of action is undetermined.
Apelin, a 36 amino acid peptide, is synthesized as part
of a 77-amino acid preproapelin precursor originally
isolated from bovine stomach extracts (Tatemoto et al,
1998) and mediates its effects via the G protein-coupled
apelin receptor, APJ (O’Dowd et al. 1993; Kawamata et al.
2001; O’Carroll et al. 2013). In addition to apelin-36,
other in vivo isoforms of the apelin peptide, such as
apelin-12, apelin-13 [including pyroglutamyl apelin-13
([Pyr1]apelin-13), the predominant isoform within the
cardiovascular system (Maguire et al. 2009)] and apelin-17
also bind to and activate APJ (Kawamata et al. 2001).
Apelin-36 and -13 may be the most abundant and
biologically active fragments (Kawamata et al. 2001).
APJ mRNA expression and apelin immunoreactivity are
present in central neural circuits and lower brainstem
structures that are involved in the modulation of BP,
including the medial parvocellular paraventricular
nucleus (PVN), the rostral ventrolateral medulla (RVLM)
and the nucleus tractus solitarius (NTS) (O’Carroll et al.
2013), and are known regulators of cardiovascular (Reaux
et al. 2001) and fluid homeostasis (O’Carroll & Lolait
2003).
Apelin expression is enhanced in the RVLM of
spontaneously hypertensive rats (SHR), a genetic model
of hypertension, compared to normotensiveWistar Kyoto
(WKY) rats (Zhang et al. 2009b) and microinjection of
an apelin-neutralizing antibody into the RVLM of SHR
significantly lowers BP (Zhang et al. 2009b) in SHR,
suggesting that the apelinergic systemmaybeup-regulated
in hypertensive disease. Moreover targeted injection of
[Pyr1]apelin-13 into the RVLM or parvocellular PVN,
or by I.C.V. injection, demonstrates increased mean
arterial blood pressure (MABP) and sympathetic nervous
system activity in the rat (Zhang et al. 2009b, 2014;
Kagiyama et al. 2005). These studies indicate that apelin
is sympathoexcitatory in the RVLM and that this as
yet unclarified mechanism is endogenously active in
the hypertensive model. A number of neuronal inputs
containing excitatory and inhibitory neurotransmitters
converge on RVLM sympathoexcitatory neurons from
multiple areas of the brain and spinal cord to control
BP by regulation of SNA; for example, endogenous
angiotensin II (AngII) (Kumagai et al. 2012) or vaso-
pressin (VP) released from PVN neurons (Kc et al.
2010) potentiate RVLM neurons, whereas GABAergic
inhibitory input from caudal ventrolateral medulla
neurons suppresses RVLM neuronal activity (Kumagai
et al. 2007), and these opposing influences regulate its
neuronal excitability. APJ has closest identity to the Ang II
receptor type AT1a (54% in transmembrane regions)
(O’Dowd et al. 1993) and the receptors share a similar
anatomical distribution (Medhurst et al. 2003), although
APJ does not bind Ang II and the effects of apelin are
independentofAT1a (Wu et al. 2014;O’Carroll et al. 2013).
Nevertheless, a direct interaction between these receptor
systems has been described, with apelin and APJ acting as
counter-regulators of the renin-angiotensin-aldosterone
system (Siddiquee et al. 2013). Additionally, APJ mRNA
expression and apelin immunoreactivity are co-localized
with VP (Reaux et al. 2001; O’Carroll & Lolait, 2003) and
oxytocin (OT) (Brailoiu et al. 2002) in magnocellular cells
of both the PVN and supraoptic nucleus (SON). We have
shown, in previous studies, that [Pyr1]apelin-13 increases
the firing rates of VP neurons in the SON (Tobin et al.
2008) and also that the in vivo effects of apelin on both
hypothalamic-neurohypophysial system (Roberts et al.,
2010) and hypothalamic-pituitary-adrenal axis (Newson
et al. 2009) neuroendocrine function are mediated
throughVP-dependentmechanisms. Furthermore, apelin
significantly stimulates VP release from rat hypothalamic
explants (Taheri et al. 2002). Therefore, possible synaptic
mechanisms connecting apelin/APJwith these peptidergic
systems may exist.
Considering the localization of apelin and APJ within
the cardiovascular neural centres, we hypothesized
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that apelin may act as a modulatory neurotransmitter
locally and/or via volume transmission to affect neuro-
transmission in the RVLM, by acting pre-synaptically
to modulate neurotransmitter release, post-synaptically
to modulate receptor function or by modulating the
excitability of local interneurons. Therefore, the present
study aimed touse blockadeofRVLMAT1,VPV1a,OT (in
the same receptor subfamily asVP receptors) or ionotropic
glutamate receptors to examine whether the pressor effect
of [Pyr1]apelin-13 evoked from the RVLM was mediated
by angiotensinergic, vasopressinergic, oxytocinergic or
glutamatergic neurotransmission. Additionally, because
RVLMsympathoexcitatory neurons are tonically inhibited
by GABAergic inputs, the effect of blockade of
RVLM GABAA receptors on [Pyr1]apelin-13-induced
sympathetic excitation andBP responseswithin theRVLM
was also determined.
Methods
Ethical approval
MaleWistar rats (250 g; Charles River, Margate, UK) were
housed under a 14:10 h light/dark cycle at 21 ± 2°C
and constant relative humidity with ad libitum access to
standard laboratory chow andwater. All experiments were
approved by the University of Bristol Animal Welfare and
Ethical Review Body and performed in strict accordance
with UK Home Office regulations (United Kingdom
Home Office Guidelines Scientific Procedures Act of
1986).
Animal preparation and BP recording
Rats (n= 6 per group) were anaesthetized by I.P. injection
of sodium pentobarbital (50 mg kg−1). All surgical
procedures were performed under aseptic conditions
under a surgical plane of anaesthesia as indicated by
the absence of withdrawal reflex to hindpaw pinch,
which was monitored throughout the procedure and
additional doses of anaesthetic given if necessary. Rats
used in the L-glutamate experiments were intubated and
ventilated with pure O2 via a tracheal cannula throughout
the experiment (60–70 strokes min−1, 1.5 ml; Harvard
Apparatus, Cambridge, MA, USA). BP was monitored via
a heparin-saline (1 U ml−1) filled catheter (0.8 mm inner
diameter; Micro-Renathane tubing; Braintree Scientific,
Braintree, MA, USA) implanted in the left or right
femoral artery and connected to a pressure transducer.
Pressure signals were amplified and filtered using aNeuro-
Log System (Digitimer, Welwyn Garden City, UK) and
recorded using a CED 1401 data capture system and Spike,
version 2.7 (Cambridge Electronic Design, Cambridge,
UK). Rats were placed in a stereotaxic frame with the head
flexed down (nose bar at −19 mm). The dorsal brainstem
was exposed followingpartial removalof theoccipital bone
and the dura mater.
RVLM microinjections
Drug solutions were prepared in accordance with the
manufacturers’ instructions, diluted to the required
concentration (consistent with a large body of literature
on the physiological effects of drugs used in the RVLM
and other brain regions) (Zhang et al. 2009a, b; Huber
& Schreihofer 2011; Zhang et al. 2014; Du et al. 2013;
Seyedabadi et al. 2002; Kc et al. 2002; Mack et al. 2002; Lu
et al. 2015) in normal saline and aliquots stored at−20°C.
RVLM injections were made using single-barrelled
micropipettes (1–5 μl calibrated microcapillary tube;
Sigma-Aldrich, Poole, UK), pulled and cut to give a tip
diameter of < 100 μm, connected to a manual pressure
injection device. The micropipette was aligned with the
caudal point of the obex as the reference with the aid
of a binocular surgical microscope (M651; Leica Micro-
systems, Milton Keynes, UK) and the RVLM was targeted
using previously established stereotaxic co-ordinates:
0.18 cm lateral from midline, 0.12 cm rostral and
0.35 cm ventral. Bilateral microinjection of L-glutamate
(1 nmol 100 nl side−1; Tocris Bioscience, Bristol, UK)
was used to confirm the position of the pipette within the
RVLM. The injection volume was determined using the
calibrationof themicropipette,where100nl corresponded
to approximately 1 mm of pipette length. Subsequent
bilateral microinjections (100 nl side−1) were made at
the same stereotaxic co-ordinates that elicited the largest
L-glutamate pressor response (> 20 mmHg). Rats were
divided into six experimental groups (n = 6 per group)
according to the receptor system being targeted (APJ, AT1,
VP V1a, OT receptor, ionotropic glutamate receptors,
GABAA). Successful receptor blockade was tested by
recording BP and heart rate (HR) responses to micro-
injections (100nl) of the respective agonist for the receptor
of interest [[Pyr1]-apelin-13, 200 pmol (Seyedabadi
et al. 2002), Bachem, Weil am Rhein, Germany; Ang II,
100 pmol (Du et al. 2013), Sigma-Aldrich; VP, 50 pmol (Kc
et al. 2002), Bachem, Germany; OT, 50 pmol (Mack et al.
2002), Bachem, Germany; L-glutamate, 1 nmol (Huber &
Schreihofer 2011), or muscimol, 2.5 pmol (Lu et al. 2015),
Tocris Bioscience] before and after microinjection of the
respective antagonist [[Ala13]apelin-13, F13A, 2 nmol
(Zhang et al. 2014), Phoenix Pharmaceuticals, Belmont,
CA, USA USA; losartan potassium, 1 nmol (Huber &
Schreihofer 2011), Tocris Bioscience; SR 49059, 200 pmol,
Sigma-Aldrich; desGly-NH2, d(CH2)5[D-Tyr2,Thr4]OVT
(dOVT), 200 pmol, gift from Professor M. Manning,
University of Toledo, Toledo, OH, USA; kynurenic
acid, 2.7 nmol (Huber & Schreihofer 2011),
Sigma-Aldrich; or 1(S),9(R)-(–)-bicucilline methiodide,
10 pmol (Zhang et al. 2009a), Sigma-Aldrich)].
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Microinjections were made in the order: saline; agonist;
[Pyr1]apelin-13; antagonist; agonist; [Pyr1]apelin-13;
saline. Apelin-dependent heterodimerization of APJ
and AT1 in vitro causes negative allosteric regulation
of AT1 (Siddiquee et al. 2013); therefore, drugs were
administered in this order to ensure that BP responses
to primary injection of Ang II would be observed. The
second injection of [Pyr1]apelin-13 was made no longer
than 5 min after the injection of antagonist, assuming no
response was observed following the second injection of
agonist. To reconfirm micropipette position within the
RVLM, a final bilateral injection of L-glutamate was made
after the final injection of [Pyr1]apelin-13. Rats therefore
received a total of nine bilateral RVLM microinjections
(900 nl RVLM−1) over the course of the entire experiment
(approximately 2.5 h). A subset of animals received a
microinjection of Indian ink (100 nl; 1:10 dilution) at the
end of the experiment to confirm the histological location
of the micropipette within the RVLM. After the final
glutamate and/or bilateral injection of Indian ink, rats
were killed using a guillotine. Brains were immediately
frozen on dry ice and stored at −80°C. Fresh, frozen
sections (40 μm) were cut using a cryostat (CM3050 S;
Leica Microsystems) and counterstained with toluidine
blue (0.1%). Sections were assessed using a Leica DM IRB
microscope and images captured (DC300 F camera; Leica
Microsystems).
Data analysis
BP waveforms from the entire experiment were processed
offline using the HRBP, version 8, for Spike 2 to extract
systolic, diastolic and mean BP and HR waveforms.
Representative APB and HR readings are shown. Data
are presented as a change in the physiological variable
by subtraction of the post-microinjection response from
the pre-microinjection baseline for each drug. Spectral
analysis of heart rate variability (HRV) and systolic blood
pressure variability (SBPV) allows the calculation of
power in the very low frequency (VLF: 0–0.3 Hz), low
frequency (LF: 0.3–0.8 Hz) and high frequency (HF:
0.8–3.3 Hz) bands (Japundzic-Zigon 1998; Parati et al.
1995). It is known that LF:HF-HRV and LF-SBPV can
be used as indicative measures of cardiac and vasomotor
sympathetic tone, respectively (Lozic´ et al. 2014; Abdala
et al. 2012); however, we have acknowledged that spectral
analysis is an indirect measure of global change in
sympathetic activity. Analysis of systolic blood pressure
and heart rate was performed using the HRV1 script
for Spike 2 to calculate power in the VLF (0–0.3 Hz),
LF (0.3–0.8 Hz) and HF (0.8–3.3 Hz) bands of across
a 500 s period, including time points before and after
microinjection of each drug. The settings used to compute
the power spectra were: time constant for DC removal:
±3 s; frequency range of spectra: 0–5.12 Hz; epoch
duration: 25 s; FFT size: 64; window type: Hanning.
Statistical analysis
All data are presented as the mean ± SEM and
were tested for statistical significance with a repeated
measures one-way ANOVA followed by Tukey’s multiple
comparison test using Prism, version 5.0 (Graphpad
Software Inc., San Diego, CA, USA). P < 0.05 was
considered statistically significant between groups (n= 6).
Results
Verification of microinjection site
Histological confirmation of the microinjection site,
and changes observed in MABP with microinjections
of L-glutamate into the RVLM, are shown in Fig. 1A
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Figure 1. Localization and verification of microinjection sites
to the RVLM
A, representative photomicrographs of toluidine blue stained
sections of the rat brainstem with bilateral indian ink (dilution 1:10)
microinjected in the position of the RVLM, with the nucleus
ambiguus circled for reference. B, schematic illustrating the
localization of injection sites (matching dots indicate bilateral
injection sites), representative of sections from each animal group,
determined by examination of the deposition of dye in the brain
stem of animals. RVLM and nucleus ambiguus (N. Amb) are
indicated. Adapted from Paxinos & Watson (1998 ; figure 68). C,
change in MABP following bilateral infusion of L-glutamate,
confirming micropipette position within the RVLM. ∗∗∗P < 0.001
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 000.00 V1a receptor mediates RVLM pressor effect of [Pyr1]apelin-13 5
and C. Figure 1A shows representative photomicrographs
of toluidine blue stained sections of the rat brainstem
with bilateral indian ink (dilution 1:10) microinjected in
the position of the RVLM. Figure 1B shows a schematic
illustrating the localization of injection sites (matching
dots indicate bilateral injection sites), representative of
sections from each animal group, which were determined
by examination of the deposition of dye in the brainstem
of animals. At these sites, microinjection of L-glutamate,
as used to assess functionally the position of the micro-
pipette in the RVLM at the beginning of each experiment
(n= 36), caused a significant increase inMABP compared
to saline (39 ± 5 mmHg compared to1 ± 1 mmHg;
P < 0.001) (Fig. 1C).
Effects of F13A microinjection into the RVLM
on [Pyr1]apelin-13-mediated BP and SNA
An ABP and HR recording following microinjection of
[Pyr1]apelin-13 pre- and post-F13A microinjection into
the RVLM is shown in Fig. 2A. The mean basal BP and
HR, calculated across rats from all groups (n = 36), were
84 ± 3 mmHg and 350 ± 9 beats min–1, respectively.
Microinjection of [Pyr1]apelin-13 (200 pmol) in the
RVLM increased MABP (9 ± 1 mmHg; P < 0.001)
(Fig. 2B) andHR (11± 4 beatsmin–1; P< 0.001) (Fig. 2C)
compared to saline-injected controls (−1 ± 2 mmHg
and −6 ± 2 beats min–1) (Fig. 2B and C). The
effect peaked at 463 ± 64 s post injection, and
had a duration of 997 ± 103 s (Fig. 2A). Micro-
injection of [Pyr1]apelin-13 into areas surrounding the
RVLM, including the facial nucleus, rubrospinal tract
and gigantocellular nucleus, had no significant effect
on MABP or HR. LF-SBP and LF:HF HR variability
spectral domains increased after [Pyr1]apelin-13 micro-
injection (13.9 ± 4.3% and 0.73 ± 0.33% total power)
(Tables 1 and 2), indicating an increase in sympathetic
drive to the vasculature and heart respectively, albeit
indirectly. Microinjection of the APJ antagonist F13A
into the RVLM abolished the [Pyr1]apelin-13-mediated
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Figure 2. Effects of APJ agonist and antagonist microinjection into the RVLM on blood pressure and
heart rate
A, raw BP and HR traces showing representative responses following the bilateral microinjection of [Pyr1]apelin-13
(200 pmol 100 nl side−1) before and after the injection of the APJ antagonist F13A (2 nmol 100 nl side−1).
Arrows mark the bilateral injection of [Pyr1]apelin-13. B and C, changes in MABP (B) and HR (C) following bilateral
microinjection of saline vehicle control and [Pyr1]apelin-13 before (white bars) and after (black bars) administration
of F13A. B and C, data are shown as the mean ± SEM (n = 6). ∗∗P < 0.01, ∗∗∗P < 0.001. Scale bars for BP, HR
and time are indicated.
C© 2017 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
6 P. R. Griffiths and others J Physiol 000.00
Table 1. Effects of agonists injected into the RVLM on LF-SBP
 LF-SBP (% total power)
Pre-F13A Post-F13A
Saline −2.2 ± 2.0 0.4 ± 1.3
[Pyr1]apelin-13 13.9 ± 4.3∗∗∗ −0.6 ± 1.5††
Pre-losartan Post-losartan
Saline 3.0 ± 2.0 1.0 ± 1.6
[Pyr1]apelin-13 11.5 ± 4.0∗ 10.4 ± 2.0∗
Ang II 13.9 ± 4.3∗ 1.0 ± 1.5‡
Pre-SR 49059 Post-SR 49059
Saline 1.3 ± 1.4 1.3 ± 1.5
DMSO 1.1 ± 1.3 0.2 ± 1.1
[Pyr1]apelin-13 19.2 ± 3.8∗∗∗+++ 1.1 ± 1.1†††
VP 16.9 ± 5.5∗∗∗+++ 1.1 ± 1.8‡‡
Pre-dOVT Post-dOVT
Saline 2.8 ± 1.8 1.3 ± 0.6
[Pyr1]apelin-13 19.2 ± 1.4∗ 17.2 ± 3.8
OT 35.6 ± 7.5∗∗∗ 2.7 ± 1.4‡‡‡
Pre-kynurenic acid Post-kynurenic acid
Saline 0.8 ± 2.0 0.8 ± 1.7
[Pyr1]apelin-13 9.8 ± 1.7∗ 8.5 ± 1.1∗
Glutamate 23.5 ± 8.1∗∗ −0.8 ± 2.0‡‡
Pre-bicuculline Post-bicuculline
Saline 0.2 ± 0.3 0.1 ± 0.2
[Pyr1]apelin-13 7.3 ± 1.1∗∗∗ 4.4 ± 0.8∗∗∗
Muscimol −8.5 ± 1.2∗∗∗ −0.7 ± 1.0‡‡‡
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. saline. +P < 0.05, ++P <
0.01, +++P < 0.001 vs. DMSO. †P < 0.05, ††P < 0.01, †††P < 0.001
[Pyr1]apelin-13 pre- vs. [Pyr1]apelin-13 post-antagonist. ‡P <
0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 Agonist pre- vs. agonist post-
antagonist.
increases in MABP (0 ± 1 mmHg; P < 0.01), HR
(−4 ± 1 beats min–1; P < 0.05) and sympathetic vaso-
motor activation (−0.6 ± 1.5% and −0.05 ± 0.04% total
power; P< 0.01 and P< 0.05) (Fig. 2A andC and Tables 1
and 2). Administration of F13A alone had no significant
effect on BP or HR (P > 0.05) (Table 3) suggesting an
absence of endogenous apelinergic drive in the RVLM of
anaesthetized rats.
Effect of blockade of angiotensin II type AT1
receptors on [Pyr1]apelin-13-induced BP
and sympathetic excitation within the RVLM
Figure 3A shows the effects of the AT1 receptor
antagonist losartan on BP and HR responses elicited by
[Pyr1]apelin-13 and Ang II injection. Bilateral micro-
injection of [Pyr1]apelin-13 in the RVLM induced an
increase in BP (12± 2mmHg; P< 0.01) (Fig. 3B) andHR
(10± 3 beatsmin–1) (Fig. 3C) compared to saline-injected
controls (0 ± 1 mmHg and –6 ± 3 beats min–1)
Table 2. Effects of agonists injected into the RVLM on LF:HF HR
 LF:HF HR
Pre-F13A Post-F13A
Saline 0.05 ± 0.03 −0.02 ± 0.01
[Pyr1]apelin-13 0.73 ± 0.33∗ −0.05 ± 0.04†
Pre-losartan Post-losartan
Saline 0.01 ± 0.01 −0.03 ± 0.03
[Pyr1]apelin-13 0.37 ± 0.15∗ 0.27 ± 0.10
Ang II −0.17 ± 0.05∗∗ −0.01 ± 0.01‡‡
Pre-SR 49059 Post-SR 49059
Saline −0.04 ± 0.03 −0.02 ± 0.01
DMSO 0.02 ± 0.02 −0.01 ± 0.02
[Pyr1]apelin-13 0.38 ± 0.11∗∗∗+++ 0.01 ± 0.01†††
VP 0.26 ± 0.07∗∗+ −0.02 ± 0.01‡‡
Pre-dOVT Post-dOVT
Saline 0.01 ± 0.01 −0.02 ± 0.03
[Pyr1]apelin-13 0.49 ± 0.15∗ 0.52 ± 0.13∗∗
OT 0.38 ± 0.18 0.07 ± 0.04
Pre-kynurenic acid Post-kynurenic acid
Saline 0.02 ± 0.02 −0.01 ± 0.01
[Pyr1]apelin-13 0.17 ± 0.03∗ 0.15 ± 0.04∗∗
Glutamate 0.42 ± 0.11∗ 0.02 ± 0.10‡
Pre-bicuculline Post-bicuculline
Saline 0.02 ± 0.01 −0.02 ± 0.02
[Pyr1]apelin-13 0.12 ± 0.01 0.17 ± 0.04∗
Muscimol 0.14 ± 0.04∗ −0.02 ± 0.04‡‡
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. saline. +P < 0.05, ++P <
0.01, +++P < 0.001 vs. DMSO. †P < 0.05, ††P < 0.01, †††P < 0.001
[Pyr1]apelin-13 pre- vs. [Pyr1]apelin-13 post-antagonist. ‡P <
0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 Agonist pre- vs. agonist post-
antagonist.
(Fig. 3B and C) and these responses were not significantly
affected by priormicroinjection of losartan into theRVLM
(P> 0.05) (Fig. 3B andC). Bilateral microinjection of Ang
II into the RVLM increased BP (11 ± 3 mmHg; P < 0.01)
(Fig. 3B) and decreased HR (−31 ± 8 beats min–1;
P < 0.01) (Fig. 3C) compared to saline-injected controls;
these responses were blocked by pretreatment with
losartan (2 ± 1 mmHg and −1 ± 2 beats min–1; P < 0.01
and P< 0.01) (Fig. 3B and C). Administration of losartan
alone did not change basal BP and HR parameters
(Table 3).
Spectral analysis of SBP and HR variability showed
that pre-injection with losartan had no effect on the
increases in SBP and HR components seen after bilateral
injection of [Pyr1]apelin-13 (P > 0.05) (Tables 1 and
2). However microinjection of Ang II raised LF-SBP
and decreased the LF:HF HRV ratio compared to saline
injected controls and pre-administration of losartan
into the RVLM abolished these responses (Tables 1
and 2).
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Table 3. Effects of receptor antagonists microinjected alone into the RVLM on BP and HR
MABP (mmHg, n = 6) HR (beats min–1, n = 6)
Saline Antagonist Saline Antagonist
F13A (2 nmol) −1 ± 2 −1 ± 4 −6 ± 2 2 ± 4
Kynurenic acid (2.7 nmol) −0 ± 2 1 ± 1 −4 ± 6 −4 ± 7
Bicuculline (10 pmol) 2 ± 2 6 ± 3 −1 ± 0 −6 ± 3
Losartan (1 nmol) 0 ± 1 3 ± 2 −6 ± 3 −3 ± 5
SR49059 (0.2 nmol) 0 ± 1 −1 ± 2 −3 ± 5 −3 ± 3
dOVT (0.2 nmol) −1 ± 1 0 ± 1 2 ± 2 2 ± 3
Values are the mean ± SEM.
Cardiovascular effects of [Pyr1]apelin-13 in the RVLM
after blockade of VP V1a or OT receptors
The effects of the VP V1a receptor antagonist SR 49059
on BP and HR responses to [Pyr1]apelin-13 and VP in
the RVLM are shown in Fig. 4A. The BP (9 ± 1 mmHg;
P< 0.001) (Fig. 4B) and HR (6± 3 beats min–1) (Fig. 4C)
responses to bilateral microinjection of [Pyr1]apelin-13
were effectively abolished after pretreatment with SR
49059 (−1± 1mmHg and−6± 4 beatsmin–1; P< 0.001)
(Fig. 3B and C). As expected, the BP and HR responses
to bilateral microinjection of VP (9 ± 1 mmHg and
−30 ± 10 beats min–1; P < 0.001 and P < 0.001) (Fig. 3B
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Figure 3. Effect of blockade of RVLM Ang II AT1 receptors on [Pyr1]apelin-13-induced cardiovascular
responses
A, raw BP and HR traces showing representative responses following the bilateral microinjection of Ang II
(100 pmol 100 nl−1) and [Pyr1]apelin-13 (200 pmol 100 nl side−1) before and after the injection of the AT1
receptor antagonist, losartan (1 nmol 100 nl side−1). Arrows mark the times of bilateral injections. B and C,
changes in MABP (B) and HR (C) following bilateral microinjection of saline vehicle control, [Pyr1]apelin-13 and
Ang II before (white bars) and after (black bars) administration of losartan. B and C, data are shown as the
mean ± SEM (n = 6). ∗∗P < 0.01. Scale bars for BP, HR and time are indicated.
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and C) were significantly decreased after pretreatment
with SR 49059 (1 ± 1 mmHg and −2 ± 5 beats min–1;
P < 0.001 and P < 0.01) (Fig. 4B and C). The response
latency and duration of BP responses to VP were 64 ± 6 s
and 346 ± 25 s respectively, which is significantly shorter
than that seen with [Pyr1]apelin-13 (P < 0.001) (Fig. 4A;
see also Fig. 2A). Bilateral microinjection of SR 49059
alone had no significant effect on ABP and HR (P> 0.05)
(Table 3).
ABPandHRrecordingsdepicting the effects of blockade
of OT receptors with dOVT on BP and HR responses
to [Pyr1]apelin-13 and OT pre- and post-antagonist
microinjection are shown in Fig. 5A. Bilateral micro-
injection of OT increased BP and HR (9 ± 1 mmHg and
−8 ± 2 beats min–1; P< 0.001 and P< 0.05) (Fig. 5B and
C) and these responses were abolished after pretreatment
with dOVT (1± 1mmHg and 1± 1 beats min–1; P< 0.01
and P < 0.05) (Fig. 5B and C). The BP (13 ± 3 mmHg;
P< 0.001) (Fig. 5B) and HR (9± 3 beats min–1) (Fig. 5C)
responses to bilateral microinjection of [Pyr1]apelin-13
wereunaffectedbypretreatmentwithdOVT(9± 1mmHg
and 6 ± 2 beats min–1) (Fig. 5B and C). Bilateral micro-
injection of dOVT alone had no significant effect on ABP
and HR (P > 0.05) (Table 3).
[Pyr1]apelin-13 microinjection-induced increases in
the LF-SBP band power and LF:HF-HRV ratio were
reduced to baseline saline-injected levels by pre-injection
of SR 49059 (P < 0.001) (Tables 1 and 2) but not by
pre-injection of dOVT (Tables 1 and 2). Pre-treatment
with either SR 49059 or dOVT, however, abolished the
cardiovascular short-term variability responses seen after
bilateralmicroinjection of VP orOT, respectively (Tables 1
and 2).
Effect of blockade of ionotropic glutamate receptors
on [Pyr1]apelin-13-induced BP and sympathetic
excitation within the RVLM
To determine whether glutamatergic activation of the
RVLM contributes to [Pyr1]apelin-13-mediated changes
in BP, HR and sympathetic drive, glutamatergic inputs to
the RVLM were blocked by bilateral microinjections of
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Figure 4. Cardiovascular effects of [Pyr1]apelin-13 in the RVLM after blockade of VP V1a receptors
A, raw BP and HR traces showing representative responses following the bilateral microinjection of VP
(50 pmol 100 nl side−1) and [Pyr1]apelin-13 (200 pmol 100 nl side−1) before and after the injection of the
VP V1a receptor antagonist, SR 49059 (200 pmol 100 nl side−1). Arrows mark the times of bilateral injections. B
and C, changes in MABP (B) and HR (C) following bilateral microinjection of saline vehicle control, [Pyr1]apelin-13
and VP before (white bars) and after (black bars) administration of SR 49059. B and C, data are shown as the
mean ± SEM (n = 6). ∗∗P < 0.01, ∗∗∗P < 0.001. Scale bars for BP, HR and time are indicated.
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kynurenate. The BP and HR responses to [Pyr1]apelin-13
and L-glutamate before and after injection of kynurenate
are shown in Fig. 6A. Bilateral injection of [Pyr1]apelin-13
into the RVLM increased BP (14 ± 3 mmHg; P < 0.001)
(Fig. 6B) and HR (11 ± 3 beats min–1) (Fig. 6C)
compared to saline-injected controls (0 ± 2 mmHg
and −4 ± 6 beats min–1) (Fig. 6B and C). The pre-
ssor and tachycardic effects of [Pyr1]apelin-13 injection
were not significantly affected by prior microinjection
of kynurenate into the RVLM (15 ± 2 mmHg and
10 ± 2 beats min–1; P > 0.05 and P > 0.05) (Fig. 6B
and C). To confirm effective blockade of ionotropic
glutamate receptors, BP and HR responses following
bilateral injection of L-glutamate were compared before
and after administration of kynurenate (BP: P< 0.01; HR:
P< 0.001) (Fig. 6B and C). Administration of kynurenate
alone resulted inminimal changes to BP andHR (Table 3).
Followingmicroinjectionof kynurenate into theRVLM,
the LF-SBP and LF:HF-HRV responses associated with
[Pyr1]apelin-13 injection were not significantly different
compared to pre-antagonist responses (P> 0.05) (Tables 1
and 2 respectively). By contrast, increases in LF-SBP and
LF:HF-HRV ratio associated with L-glutamate injection
were attenuated following kynurenate injection to the
RVLM (Tables 1 and 2).
Effect of blockade of GABAA receptors on
[Pyr1]apelin-13-induced BP and sympathetic
excitation within the RVLM
ABP and HR recordings of the effects of blockade
of GABAA receptors with bicuculline on BP and HR
responses to [Pyr1]apelin-13 and muscimol pre- and
post-antagonist microinjection are shown in Fig. 7A.
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Figure 5. Effect of RVLM oxytocin receptor antagonist microinjection on [Pyr1]apelin-13-induced cardio-
vascular responses
A, raw BP and HR traces showing representative responses following the bilateral microinjection of OT
(50 pmol 100 nl side−1) and [Pyr1]apelin-13 (200 pmol 100 nl side−1) before and after the injection of the
OT receptor antagonist, dOVT (200 pmol 100 nl side−1). Arrows mark the times of bilateral injections. B and C,
changes in MABP (B) and HR (C) following bilateral microinjection of saline vehicle control, [Pyr1]apelin-13 and OT
before (white bars) and after (black bars) administration of dOVT. B and C, data are shown as the mean ± SEM
(n = 6). ∗P < 0.05, ∗∗∗P < 0.001. Scale bars for BP, HR and time are indicated.
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Pre-treatment with bicuculline did not significantly
change the increases in MABP (13 ± 3 mmHg; P < 0.01)
(Fig. 7B) or HR (16 ± 6 beats min–1; P < 0.05)
(Fig. 7C) inducedby themicroinjectionof [Pyr1]apelin-13
into the RVLM compared to saline-injected controls
(−1 ± 1 mmHg and −3 ± 1 beats min–1) (Fig. 7B and
C). Prior to bicuculline microinjection, microinjection
of muscimol into the RVLM reduced baseline MABP
and increased HR compared to saline-injected controls
(P < 0.01) Fig. 7B and C) and these BP and HR responses
were abrogated after blockade of GABAA receptors in the
RVLM (P < 0.01) (Fig. 7B and C). Bicuculline injection
alone caused small changes in ABP and HR; however,
these were not significantly different compared to saline
(P > 0.05) (Table 3).
Similarly, the increases in LF-SBP band power and
the LF:HF-HRV ratio seen after [Pyr1]apelin-13 micro-
injection into the RVLM compared to saline pretreatment
were unaffected by pre-injection of bicuculline (P> 0.05)
(Tables 1 and 2). Pre-treatment with this antagonist
however reduced the LF-SBP band power and the
LF:HF-HRV ratio responses seen after bilateral micro-
injection of muscimol (Tables 1 and 2).
Discussion
In the present study, we show that the pressor effect
evoked in the RVLM by bilateral microinjection of
[Pyr1]apelin-13 is dependent on VP V1a receptor
activation. On the other hand, blockade of AT1, OT,
ionotropic glutamate or GABAA receptors in the RVLM
has no effect on the pressor and sympathoexcitatory
response evoked by [Pyr1]apelin-13.
Bilateral microinjection of [Pyr1]apelin-13 into the
RVLM of Wistar rats increased BP and sympathetic
vasomotor tone (as indirectly measured by spectral
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Figure 6. Effect of blockade of RVLM ionotropic glutamate receptors on [Pyr1]apelin-13-induced cardio-
vascular responses
A, raw BP and HR traces showing representative responses following the bilateral microinjection of L-glutamate
(1 nmol 100 nl side−1) and [Pyr1]apelin-13 (200 pmol 100 nl side−1) before and after the injection of the
ionotropic glutamate receptor antagonist, kynurenic acid (2.7 nmol 100 nl side−1). Arrows mark the times of
bilateral injections. B and C, changes in MABP (B) and HR (C) following bilateral microinjection of saline vehicle
control, [Pyr1]apelin-13 and L-glutamate before (white bars) and after (black bars) administration of kynurenic
acid. B and C, data are shown as the mean ± SEM (n = 6). ∗∗P < 0.01, ∗∗∗P < 0.001. Scale bars for BP, HR and
time are indicated.
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analysis of BP), which is consistent with previous
studies in normotensive WKY (Zhang et al. 2009b)
and Sprague–Dawley (Seyedabadi et al. 2002) rats. The
rise in [Pyr1]apelin-13-mediated BP was associated with
an increase in the low frequency spectra of systolic
BP, indicative of sympathetic vasomotor activation,
and an increase in LF:HF HRV, a measure of
sympathovagal balance, suggesting a predominantly
sympathetic influence (Malliani et al. 1991). There was
no obvious autonomically mediated chronopic effect
following microinjection of apelin; thus, vagal drive to
the heart may not be influenced by the apelin-mediated
pressor response. Inconsistent effects of I.V. injected
apelin on HR have been reported previously, showing
either an increase (Mitra et al. 2006) or no effect
(Reaux et al. 2001). Pre-treatment with the specific
APJ antagonist, F13A (Lee et al. 2005), abolished the
[Pyr1]apelin-13-induced pressor activity and sympathetic
outflow; however, the administration of F13A alone did
not produce a depressor response, suggesting that, if apelin
is endogenously released, it is not associated with tonic
neural control of resting cardiovascular activity in the
RVLM of normotensive rats.
In the mouse, apelin-13 has been shown to alter
the consolidation of passive avoidance learning and to
exhibit anxiolytic-like activity via multiple peripheral
mechanisms, includingα-adrenergic, 5-HT2 serotonergic,
cholinergic, dopaminergic and GABAAergic systems
(Telegdy et al. 2013; Telegdy & Ja´szbere´nyi 2014). Because
these findings suggest that apelin may have a role as a
modulatory neurotransmitter, we proceeded to explore
the possible mechanisms by which [Pyr1]apelin-13 in the
RVLM affects MABP and SNA. We evaluated the role
of Ang II, VP, glutamate and GABA neurotransmission
on the cardiovascular effects mediated by bilateral RVLM
[Pyr1]apelin-13microinjection. Ang II, acting via the AT1
receptor expressed in the RVLM, is known to function as
an excitatory modulator increasing BP and sympathetic
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Figure 7. Cardiovascular effects of [Pyr1]apelin-13 in the RVLM after blockade of GABAA receptors
A, raw BP and HR traces showing representative responses following the bilateral microinjection of muscimol
(2.5 pmol 100 nl side−1) and [Pyr1]apelin-13 (200 pmol 100 nl side−1) before and after the injection of the GABAA
receptor antagonist, bicuculline (10 pmol 100 nl side−1). Arrows mark the times of bilateral injections. B and C,
changes in MABP (B) and HR (C) following bilateral microinjection of saline vehicle control, [Pyr1]apelin-13 and
muscimol before (white bars) and after (black bars) administration of bicuculline. B and C, data are shown as the
mean ± SEM (n = 6). ∗P < 0.05, ∗∗P < 0.01.
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outflow (Mayorov & Head 2003a), as well as increasing
the excitability of spinally projecting PVN neurons by
attenuation of GABAergic synaptic inputs (Li et al. 2003),
whereas VP is a potent vasoconstrictor and the pressor
responses of excitatory amino acids injected into the brain
have been shown to bemediated via VP release (Pizzirusso
et al. 1998). Additionally L-glutamate andGABA receptors
play important roles in the synaptic regulation of RVLM
central pressor responses (Dampney 1994). L-glutamate
regulates neuron excitability, increasing BP and SNA
(Guyenet 2006) and enhancing the sympathetic baroreflex
(Mayorov & Head 2003b), whereas tonic inhibition of
vasopressor neurons in the RVLM by endogenous GABA
is well established (Heesch et al. 2006) and may play a role
in modifying the responsiveness of these neurones to the
effects of sympathoexcitatory neurotransmitters.
We show that bilateral microinjection of the selective
antagonist losartan to block AT1 receptors in the RVLM
does not affect [Pyr1]apelin-13-mediated increases in BP
or SNA in normotensive animals. This suggests that Ang
II does not mediate the sympathoexcitatory response to
[Pyr1]apelin-13 in this region. The absence of changes in
BP and sympathetic outflow seen in the present study is
in accordance with previous studies where I.C.V. or PVN
injection of the AT1 receptor antagonists CV-11974 or
losartan, respectively, were ineffective at preventing the
BP and SNA effects of I.C.V. (Kagiyama et al. 2005) or
PVN- (Zhang et al. 2014) injected apelin. Thus, despite
APJ sharing highest sequence homology with the AT1
receptor (O’Dowd et al. 1993) and the fact that these
two receptors appear to heterodimerize, at least in vitro
(Siddiquee et al. 2013), the cardiovascular effects of
central apelin do not appear to be mediated via AT1
receptors in normotensive animals.
The apelin–APJ system may also act indirectly via
regulation of vasopressinergic neuron activity to affect
vascular tone. VP neurons project from the PVN to
the RVLM where V1a receptor immunoreactivity is
established in RVLM-spinal vasomotor neurons (Kc et al.
2010) and a combination of actions of PVN-induced VP
release in the NTS and RVLM has been postulated to
elevate arterial BP (Vallejo et al. 1984; Sun & Guyenet
1989). We therefore investigated whether the apelin-APJ
system may act via VP to affect cardiovascular responses
in the RVLM.We show that bilateral microinjection of VP
into theRVLMofWistar rats increasesBPand sympathetic
vasomotor tone, and decreases HR; responses that are
abolished aftermicroinjectionof theVPV1a antagonist SR
49059 in theRVLM. Importantly,microinjectionSR49059
is also effective in blocking the [Pyr1]apelin-13-induced
increases in MABP, HR and sympathetic tone, suggesting
that [Pyr1]apelin-13 acting in the RVLM increases BP
and vasomotor tone via a vasopressinergic mechanism.
As found for apelin, inconsistent HR responses have been
reported previously following the microinjection of VP
into the RVLM, where variable and non-dose-related
changes are observed in the RVLM (Gomez et al. 1993)
and NTS (Lawrence & Jarrott, 1995), whereas topical
application of VP to the ventral surface of the RVLM
does not result in consistent or significant tachycardia
(Andreatta-Van Leyen et al. 1990). Therefore, it is difficult
to draw conclusions from the results of the present study
regarding the interplay of apelin and VP in the control of
HR via the RVLM.
V1a and OT receptors appear to be differentially
distributed within the RVLM, with VP V1a receptors
expressed throughout the rostro-caudal axis (Kc et al.
2010) and OT receptors confined to a small population
of neurons in the pre-Botzinger complex (Mack et al.
2002). Whether any colocalization of the two receptors
exists, or whether there is functional cross-talk between
the two receptor systems in the RVLM, is not known.
However, given the relatively high affinity of OT for the
VP V1a receptor (Chini & Manning 2007), OT may also
be active in modulating BP via RVLM VP V1a receptors.
Therefore, we investigated the effect of bilateral micro-
injection of OT in the RVLM on BP responses. OT
microinjection increased MABP and HR in the RVLM
compared to saline-injected controls; responses that were
completely abolished after pretreatment with the highly
specific OT receptor antagonist dOVT (Manning et al.
2012), indicating thatOTdoes notmodulate BP viaRVLM
VP V1a receptors at the ligand doses used in the present
study. Furthermore, cardiovascular responses to bilateral
microinjection of [Pyr1]apelin-13 were not affected by
pre-treatment with dOVT, suggesting that the pressor
action of [Pyr1]apelin-13 in the RVLM normotensive rats
is not mediated via OT receptors. Experiments performed
in rats in which OT has been knocked down, or in
OT knockout mice, may clarify which neurohypophysial
hormone is primarily active in the cardiovascular actions
mediated via the RVLM.
The precise nature of the interaction between APJ and
V1a receptors at the level of the RVLM is not known;
however, there is interplay between the apelinergic and
vasopressinergic systems in the hypothalamus where a
cross-regulation of endogenous levels of apelin and VP
has been described (Reaux-Le Goazigo et al. 2004), as
well as in the renal collecting duct where cross-talk
between APJ- and VP V1a receptor-mediated signalling
has beenproposed (Hus-Citharel et al. 2014).Additionally,
we have shown that [Pyr1]apelin-13 increases the firing
rate of VP neurons in the isolated SON; such activation
invariably correlates with increased VP terminal secretion
that may be mediated in part through apelin-induced
inhibition of dendritic VP release within the SON (Tobin
et al. 2008). Such an interaction, which may involve
receptor dimerization as is seen in other GPCR systems
(Milligan 2009), may be explored in ongoing studies in
in vitro systems with cells co-expressing both receptors or
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using bioluminescence or fluorescence resonance energy
transfer to monitor protein–protein interactions.
Primary neurotransmitters also implicated in excitatory
and inhibitory synaptic inputs to sympathoexcitatory
RVLM neurons are glutamate and GABA, mediated by
ionotropic glutamate and GABAA receptors, respecti-
vely (Sun &Guyenet 1985, Sun &Guyenet 1986). A recent
report has demonstrated that blockade of NMDA and
non-NMDA glutamate receptors in the PVN attenuates
the pressor and sympathetic activity response to apelin-13
in the PVN in SHR (Zhang et al. 2014). The contra-
sting data of the present study, where no effect on
[Pyr1]apelin-13-mediated increases in BP or SNA is seen
after blockade of ionotropic glutamate receptors, may
reflect the region studied (RVLM vs. PVN) and/or the
physiological condition of the animals (normotensive vs.
SHR). Altered synaptic transmission has been shown in
cardiovascular regulatory centres in hypertension models
(Wang et al. 2009) and both apelin (Zhang et al. 2009b)
and glutamate (Li et al. 2014) receptors are upregulated in
the RVLM of SHR, a model of essential hypertension that
has an increased basal vasomotor tone. Thus, theremay be
a shift in the balance of inhibitory and excitatory inputs
in SHR brain regions to produce variable physiological
changes not seen in the normotensive state. Additionally,
blockade of GABAA receptors had no effect on baseline BP
in the RVLM or on the pressor and sympathoexcitatory
response evoked by [Pyr1]apelin-13, suggesting that the
mechanism by which apelin excites RVLM neurons is
independent of GABAergic neurotransmission.
Conceivably, [Pyr1]apelin-13 injection, acting via APJ
located on VP fibres within the RVLM, induces the
release of VP with consequent pressor effects; it is
also possible that APJ cross-talks with the VP V1a
receptor on RVLM neuronal cell bodies to modulate
agonist-induced pressor effects (Fig. 8). The elevation
in BP is more prolonged when injecting [Pyr1]apelin-13
compared to VP at the same RVLM site. Factors that
may contribute to this ‘longer’ time course may include
multiple actionswhere apelinmay act at different locations
within the RVLM (e.g. different cell/fibre populations)
with varying pharmacokinetics. There is evidence for
functional heterogeneity in apelin electrophysiological
responses (e.g. mainly depolarization, as well as hyper-
polarization in some neurons) in other brain regions such
as the arcuate nucleus (Lee et al. 2015) and subfornical
organ (Dai et al. 2013). This proposed system may be
indicative of a complex mechanism in controlling the
physiological functions of endogenous apelin that may
be important in a hypertensive disease state, in which
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Figure 8. Schematic interpretation of VP V1a receptor mediation of the central hypertensive effect of
[Pyr1]apelin-13
[Pyr1]apelin-13 injection, acting via APJ located on presynaptic VP fibres within the RVLM, induces the release
of VP with consequent pressor effects. Additionally, APJ located on the postsynaptic membrane of RVLM bulbo-
spinal neurons may interact with the VP V1a receptor (e.g. receptor dimerization) to modulate agonist induced
pressor effects. VP release from PVN-RVLM projecting fibres could also be affected by the presence of pre-
synaptic VP V1a receptors. Potential sources of endogenous apelin are indicated (1) to (4). Apelin could (1) be
co-localized with VP in PVN-RVLM projecting fibres (apelin-immunoreactive cell bodies have been described in
the magnocellular region of the PVN (Reaux et al. 2001)); (2) be present in non-VP-ergic fibres projecting to the
RVLM; (3) be found in (and released from) local neurons within the RVLM neuronal network (the apelin gene is
transcribed in the RVLM (Zhang et al. 2009b) and our unpublished observations); and/or (4) reach the RVLM via
volume transmission. [Colour figure can be viewed at wileyonlinelibrary.com]
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apelin secretion increases BP by inducing VP release.
Further studies are needed to determine whether there
are other vasoactive peptides with which apelin and APJ
may interact, aswell as the specificmechanisms involved in
the regulationof [Pyr1]apelin-13-mediated cardiovascular
control within the RVLM.
In conclusion, the results of the present study confirm
that microinjection of [Pyr1]apelin-13 into the RVLM
increases mean arterial pressure and SNA, and that these
effects are mediated via APJ, suggesting that this peptide
system may play an important role in cardiovascular
regulation at the level of the RVLM in specific physio-
logical situations and should be considered as a potential
target for therapeutic strategies that are used to reverse
hypertensive pathology.We show that [Pyr1]apelin-13 acts
as a modulating neurotransmitter in the normotensive
rat RVLM to facilitate synaptic transmission and that
[Pyr1]apelin-13-induced sympathoexcitation acts via the
VPV1a receptor to affect vascular tone, but is independent
of AT1, OT, ionotropic glutamate and GABAA receptors.
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